You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 20, 2025

CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000468 ↗ Myocardial Infarction Triage and Intervention Project (MITI) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1988-04-01 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00000468 ↗ Myocardial Infarction Triage and Intervention Project (MITI) Completed University of Washington Phase 3 1988-04-01 To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy.
NCT00182143 ↗ PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) Completed Australian and New Zealand Intensive Care Society Clinical Trials Group Phase 3 2006-05-01 The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container

Condition Name

Condition Name for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Covid19 4
Myocardial Infarction 4
Healthy 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container
Intervention Trials
Thrombosis 13
Venous Thrombosis 7
Acute Kidney Injury 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container

Trials by Country

Trials by Country for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container
Location Trials
United States 44
China 16
Canada 14
Brazil 12
Germany 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container
Location Trials
California 7
New York 5
Texas 4
Ohio 3
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Phase 4 27
Phase 3 15
Phase 2/Phase 3 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container
Clinical Trial Phase Trials
Completed 47
Unknown status 13
Withdrawn 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container

Sponsor Name

Sponsor Name for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
Ain Shams University 5
GlaxoSmithKline 4
Azidus Brasil 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Heparin Sodium 5,000 Units In Sodium Chloride 0.9% In Plastic Container
Sponsor Trials
Other 143
Industry 35
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Heparin Sodium 5,000 Units in Sodium Chloride 0.9% in Plastic Container: Clinical Trials, Market Analysis, and Projections

Introduction

Heparin sodium, a widely used anticoagulant, has been a cornerstone in the prevention and treatment of thromboembolic disorders for over half a century. This article delves into the current clinical trials, market analysis, and future projections for heparin sodium, specifically the formulation of 5,000 Units in sodium chloride 0.9% in plastic containers.

Clinical Trials Update

Phase I Study on Heparin Sodium

A recent Phase I study, conducted by União Química, focuses on the pharmacodynamic profile of heparin sodium of porcine origin in intravenous administration. This study aims to evaluate the pharmacodynamic and pharmacokinetic profiles, as well as the toxicity of the product in healthy male participants. The study adheres to the guidelines set by the ANVISA (National Health Surveillance Agency) Heparin Development Guide[1][4].

Objectives and Methodology

The primary objective is to assess the safety and efficacy of heparin sodium in humans, particularly since this is the first biological product developed by União Química. The study involves comparing the test product with a control heparin to evaluate the results without the need to demonstrate bioequivalence among the evaluated products.

Expected Outcomes

Given that unfractionated sodium heparin is well-established and widely used, no unknown adverse events or risks are anticipated. However, the study will provide valuable data on the pharmacodynamic and pharmacokinetic profiles, which are crucial for further product development and regulatory approvals.

Mechanism of Action

Interaction with Antithrombin III

Heparin sodium works by interacting with the naturally occurring plasma protein Antithrombin III, inducing a conformational change that enhances the serine protease activity of Antithrombin III. This interaction inhibits the activated coagulation factors, particularly Factor Xa and Factor IIa (thrombin), thereby preventing the formation of a stable fibrin clot[3].

Clinical Implications

This mechanism is critical in the prevention and treatment of venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter, and other conditions. The effectiveness of heparin in inhibiting coagulation factors makes it a vital component in various clinical settings.

Market Analysis

Global Heparin Market

The global heparin market, which includes heparin sodium, was valued at USD 7.42 billion in 2022 and is projected to reach USD 10.93 billion by 2030, growing at a CAGR of 5.05% during the forecast period of 2023 to 2030[5].

Market Segmentation

The market is segmented based on product type (unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin), mode of administration (parenteral and oral), source (bovine and porcine), and application (pre-surgical procedures, post-surgical procedures, kidney dialysis, etc.). The segment of hospitals dominates the end-user market due to the high demand for the drug[5].

Heparin Sodium Injection Market

The heparin sodium injection market, specifically, is anticipated to grow at a faster pace. The market is categorized based on application (treatment of venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter, etc.) and product concentration (1,000 USP Units/mL, 5,000 USP Units/mL, 10,000 USP Units/mL)[2].

Market Projections

Growth Drivers

The growth of the heparin sodium market is driven by several factors, including an increase in research and development activities, rising clinical trials, and the launch of new products. Technological advancements and investments in emerging markets are also expected to fuel market growth[5].

Geographical Insights

The market is geographically segmented into North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa. Each region presents unique opportunities and challenges, with the Asia-Pacific region expected to show significant growth due to increasing healthcare demands and investments in healthcare infrastructure[2].

Restraints and Challenges

Despite the positive outlook, the market faces challenges such as the high cost associated with heparin sodium products. This can limit accessibility, especially in regions with limited healthcare resources. However, ongoing innovations and regulatory support are expected to mitigate these challenges over time[5].

Product Formulation and Packaging

Heparin Sodium in Sodium Chloride 0.9%

The formulation of heparin sodium in 0.9% sodium chloride solution is widely used and available in various concentrations, including 5,000 USP Units/mL. This solution is packaged in flexible plastic containers, which are fabricated from polyvinylchloride or polyolefin plastic. These containers are designed to ensure the stability of the solution, although minor leaching of chemical components can occur[3].

Key Takeaways

  • Clinical Trials: Ongoing Phase I studies are evaluating the pharmacodynamic and pharmacokinetic profiles of heparin sodium of porcine origin.
  • Mechanism of Action: Heparin sodium inhibits coagulation factors by interacting with Antithrombin III.
  • Market Analysis: The global heparin market is projected to grow significantly, driven by research and development, clinical trials, and technological advancements.
  • Market Projections: The heparin sodium injection market is expected to grow, with key drivers including increasing healthcare demands and investments in emerging markets.
  • Product Formulation: Heparin sodium in 0.9% sodium chloride solution is a common formulation, available in various concentrations and packaged in flexible plastic containers.

FAQs

What is the primary mechanism of action of heparin sodium?

Heparin sodium works by interacting with Antithrombin III, enhancing its serine protease activity to inhibit coagulation factors such as Factor Xa and Factor IIa.

What are the key applications of heparin sodium?

Heparin sodium is used in the treatment of venous thromboembolism, complications of pregnancy, cardioversion of atrial fibrillation/flutter, and other conditions.

What is the projected growth rate of the global heparin market?

The global heparin market is expected to grow at a CAGR of 5.05% from 2023 to 2030.

What are the challenges facing the heparin sodium market?

One of the main challenges is the high cost associated with heparin sodium products, which can limit accessibility in some regions.

What is the significance of the ongoing clinical trials for heparin sodium?

The ongoing clinical trials aim to evaluate the safety and efficacy of heparin sodium of porcine origin, providing crucial data for further product development and regulatory approvals.

Sources

  1. Study With Heparin Sodium in Intravenous Administration. CTV Veeva.
  2. Global Heparin Sodium Injection Market Size and Forecast. Market Research Intellect.
  3. Heparin Sodium in 0.9% Sodium Chloride Injection. Pfizer Medical Information.
  4. Study With Heparin Sodium in Intravenous Administration. Network of Care.
  5. Global Heparin Market – Industry Trends and Forecast to 2030. Data Bridge Market Research.
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.